ClinVar Miner

Submissions for variant NM_007294.3(BRCA1):c.5297T>G (p.Ile1766Ser) (rs80357463)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 8
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) RCV000031237 SCV000244396 pathogenic Breast-ovarian cancer, familial 1 2015-08-10 reviewed by expert panel curation IARC class based on posterior probability from multifactorial likelihood analysis, thresholds for class as per Plon et al. 2008 (PMID: 18951446). Class 5 based on posterior probability = 1
Invitae RCV000048915 SCV000076928 likely pathogenic Hereditary breast and ovarian cancer syndrome 2018-11-30 criteria provided, single submitter clinical testing This sequence change replaces isoleucine with serine at codon 1766 of the BRCA1 protein (p.Ile1766Ser). The isoleucine residue is highly conserved and there is a large physicochemical difference between isoleucine and serine. This variant is not present in population databases (rs80357463, ExAC no frequency). This variant has been reported in individuals affected with breast and/or ovarian cancer (PMID: 20737206, 17308087). ClinVar contains an entry for this variant (Variation ID: 37656). Experimental studies have shown that this missense change affects BRCA1 peptide binding specificity, protease sensitivity and transcriptional activity (PMID: 17305420, 20516115, 17308087, 16528612, 14534301). It also inhibits growth suppression in an in vitro assay (PMID: 19493677, 18680205). In addition, multifactorial likelihood analyses developed to assess the clinical relevance of BRCA1 variants predict that this variant is deleterious (PMID: 21990134, 17924331, 27272900). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic.
Ambry Genetics RCV000218342 SCV000277074 pathogenic Hereditary cancer-predisposing syndrome 2015-07-17 criteria provided, single submitter clinical testing
Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA), c/o University of Cambridge RCV000031237 SCV000326252 pathogenic Breast-ovarian cancer, familial 1 2015-10-02 criteria provided, single submitter clinical testing
Color RCV000218342 SCV000683284 pathogenic Hereditary cancer-predisposing syndrome 2017-02-10 criteria provided, single submitter clinical testing
Sharing Clinical Reports Project (SCRP) RCV000031237 SCV000053838 pathogenic Breast-ovarian cancer, familial 1 2010-04-09 no assertion criteria provided clinical testing
Breast Cancer Information Core (BIC) (BRCA1) RCV000031237 SCV000145442 uncertain significance Breast-ovarian cancer, familial 1 2004-02-20 no assertion criteria provided clinical testing
Research Molecular Genetics Laboratory,Women's College Hospital, University of Toronto RCV000048915 SCV000587489 pathogenic Hereditary breast and ovarian cancer syndrome 2014-01-31 no assertion criteria provided research

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.